ExeVir develops novel antibody therapies utilizing a modular platform based on camelid antibody fragments (VHH) for infectious disease control. This technology creates stable, cost-effective therapeutic compounds capable of binding multiple conserved epitopes on pathogens. The company is advancing a pipeline focused initially on COVID-19 and dengue to address public health threats, particularly for vulnerable patient populations.
Funding
$76.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AIFounders
Product
Problem
The increasing global population and climate change are contributing to a rise in the incidence and rapid spread of infectious diseases, creating a need for effective prevention and treatment strategies. Current therapeutic options may not always be readily adaptable to emerging variants or subtypes of viral and bacterial infections, particularly for vulnerable patient populations.
Solution
ExeVir Bio is developing a pipeline of novel antibody therapies based on camelid-derived single-domain antibody fragments (VHHs) to address the growing impact of infectious diseases. Their modular platform technology uses these VHHs as building blocks to create therapeutic compounds that are stable, cost-effective, and easy to produce. These constructs can bind to multiple epitopes on a bacterial cell or viral particle, offering an advantage against emerging disease variants and subtypes. The company's approach aims to provide rapid and agile responses to current and future public health threats, with an initial focus on COVID-19 and dengue, particularly for immunocompromised patients.
Target Audience
The primary target audience includes immunocompromised patients, individuals at high risk of infectious diseases, and strategic partners for the co-development of novel therapeutics.
Features
- Modular platform technology utilizing camelid antibody fragments (VHHs)
- Multi-specific single domain antibodies capable of binding multiple epitopes
- Stable and cost-effective production of antibody therapies
- Pipeline focused on addressing infectious diseases, including COVID-19 and dengue
- Ability to fast-track antibody drug development